Weekly Investment Analysts’ Ratings Changes for Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals (NASDAQ: ARWR) recently received a number of ratings updates from brokerages and research firms:

• 7/27/2026 – Arrowhead Pharmaceuticals had its price target raised by HC Wainwright from $100.00 to $115.00. They now have a “buy” rating on the stock.
• 7/23/2026 – Arrowhead Pharmaceuticals had its price target raised by Morgan Stanley from $100.00 to $120.00. They now have an “overweight” rating on the stock.
• 7/23/2026 – Arrowhead Pharmaceuticals had its “overweight” rating reaffirmed by Piper Sandler. They now have a $126.00 price target on the stock, up from $110.00.
• 7/22/2026 – Arrowhead Pharmaceuticals had its price target raised by Chardan Capital from $90.00 to $115.00. They now have a “buy” rating on the stock.
• 7/17/2026 – Arrowhead Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $88.00 to $95.00. They now have an “overweight” rating on the stock.
• 7/14/2026 – Arrowhead Pharmaceuticals is now covered by Stifel Nicolaus. They set a “buy” rating and a $98.00 price target on the stock.
• 7/1/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.
• 6/30/2026 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by Chardan Capital. They now have a $90.00 price target on the stock.
• 6/27/2026 – Arrowhead Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 6/17/2026 – Arrowhead Pharmaceuticals had its price target raised by Leerink Partners from $61.00 to $72.00. They now have a “market perform” rating on the stock.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, Director Hongbo Lu sold 2,970 shares of the company’s stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total value of $228,333.60. Following the completion of the sale, the director directly owned 52,012 shares in the company, valued at $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.60% of the stock is currently owned by corporate insiders.

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.